Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SILOBullishCorporate Developmentsnews

High materiality8/10

SILO secures European patent for SPC-15 PTSD prevention, expanding IP moat

Aug 10, 2026, 8:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

IP expansion and a key licensing deal reduce execution risk for SPC-15, potentially lifting valuation despite ongoing development; limited near-term revenue, so impact may be modest unless milestones or partnerships are announced.

AI summary

What happened, with direct paths to the underlying reporting

Silo Pharma announced that the European Patent Office granted EP3952852 for SPC-15's preventive, nose-to-brain approach to PTSD, reinforcing an IP moat and global development rights under an exclusive license with Columbia University. The patent cites prophylactic efficacy of 5-HT4 receptor agonists and could support European commercialization partnerships and broaden SPC-15's risk-adjusted value.

European patent granted for SPC-15 PTSD prophylaxis. Strengthens IP moat and EU reach.
EP3952852 covers prophylactic efficacy against stress via 5-HT4 agonists.
Silo holds exclusive European license with Columbia University for SPC-15.
Preventive approach could shift PTSD care paradigm, per CEO.
EU patent complements five other major global markets.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.